Table 1.

Pooled risk estimates (and 95% confidence intervals) for AML and five lymphoma subtypes stratified by start of follow-up and AML significance level and including data from Sorahan et al. (2005).

Lymphoma subtype/AML significance level^a	No. of studies	No. of cases	Meta relative risk (all studies)	No. of cases	Meta risk ratio (start follow-up before 1970)	No. of studies	Meta risk ratio (start follow-up 1970 and later)
AML
A–E (all studies)	22	229	1.69 (1.38–2.08)*	13	131	1.47 (1.12–1.92)*	9	98	2.08 (1.59–2.72)
A–D	22	229	1.69 (1.38–2.08)*	13	131	1.47 (1.12–1.92)*	9	98	2.08 (1.59–2.72)
A–C	17	204	1.87 (1.57–2.22)	9	112	1.72 (1.38–2.15)	8	92	2.11 (1.61–2.77)
A–B	12	144	2.15 (1.76–2.63)	6	76	1.99 (1.51–2.60)	6	68	2.41 (1.77–3.29)
A	10	120	2.38 (1.89–2.99)	5	63	2.13 (1.57–2.89)	5	57	2.88 (1.95–3.99)
HL
A–E (all studies)	28	149	1.00 (0.84–1.18)	20	126	1.01 (0.84–1.23)	8	23	0.91 (0.59–1.40)
A–D	13	72	0.99 (0.78–1.27)	9	61	1.03 (0.79–1.35)	4	11	0.83 (0.47–1.48)
A–C	10	42	0.84 (0.61–1.16)	6	31	0.84 (0.57–1.24)	4	11	0.83 (0.47–1.48)
A–B	6	10	0.57 (0.30–1.10)	3	9	0.65 (0.31–1.38)	3	1b	0.40 (0.11–1.44)
A	5	10	0.61 (0.31–2.19)	3	9	0.65 (0.31–1.38)	2	1c	0.46 (0.10–2.09)
NHLd
A–E (all studies)	34	662	1.00 (0.89–1.12)*	23	467	0.93 (0.82–1.05)	11	195	1.21 (0.94–1.55)*
A–D	16	398	0.96 (0.81–1.14)	9	223	0.83 (0.68–1.01)	7	175	1.18 (0.91–1.53)*
A–C	14	359	0.98 (0.81–1.18)	7	184	0.83 (0.65–1.05)	7	175	1.18 (0.91–1.53)*
A–B	8	145	1.16 (0.85–1.57)	3	55	0.89 (0.62–1.27)	5	90	1.38 (0.92–2.06)*
A	7	116	1.10 (0.78–1.55)	3	55	0.89 (0.62–1.27)	4	61	1.40 (0.79–2.51)*
MM
A–E (all studies)	27	290	1.11 (0.97–1.26)	17	210	1.06 (0.92–1.22)	10	80	1.26 (0.92–1.71)
A–D	15	166	1.13 (0.93–1.37)	8	111	1.06 (0.87–1.30)	7	55	1.27 (0.81–2.00)*
A–C	13	143	1.15 (0.91–1.44)	6	88	1.08 (0.86–1.34)	7	55	1.27 (0.81–2.00)*
A–B	8	75	1.40 (1.02–1.90)	3	35	1.20 (0.73–2.00)	5	40	1.58 (1.03–2.44)
A	7	62	1.42 (0.97–2.08)	3	35	1.20 (0.73–2.00)	4	27	1.75 (0.94–3.26)
ALL
A–E (all studies)	18	47	1.41 (1.02–1.97)	11	30	1.27 (0.86–1.87)	7	17	1.92 (1.00–3.67)
A–D	18	47	1.41 (1.02–1.97)	11	30	1.27 (0.86–1.87)	7	17	1.92 (1.00–3.67)
A–C	12	29	1.36 (0.88–2.10)	6	15	1.04 (0.60–1.81)	6	14	2.10 (1.04–4.25)
A–B	8	16	1.59 (0.85–2.99)	3	5	0.98 (0.38–2.58)	5	11	2.28 (0.99–5.26)
A	6	12	1.52 (0.71–3.26)	2	3	0.88 (0.27–2.81)	4	9	2.30 (0.84–6.29)
CLL
A–E (all studies)	19	116	1.16 (0.81–1.65)*	12	74	0.91 (0.56–1.48)*	7	42	1.63 (1.09–2.44)
A–D	19	116	1.16 (0.81–1.65)*	12	74	0.91 (0.56–1.48)	7	42	1.63 (1.09–2.44)
A–C	14	98	1.20 (0.78–1.84)*	8	60	0.91 (0.47–1.75)	6	38	1.61 (1.00–2.59)
A–B	9	62	1.37 (0.80–2.35)*	5	43	1.13 (0.43–2.97)	4	19	1.84 (1.12–3.02)
A	7	50	1.36 (0.74–2.51)	4	41	1.40 (0.49–4.01)	3	9	1.33 (0.64–2.76)
Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; HL, Hodgkin lymphoma; MM, multiple myeloma; NHL, non-Hodgkin lymphoma. Data presented here correspond to Supplemental Material, Table 1 from Vlaanderen et al. (2011; http://dx.doi.org/10.1289/ehp.1002318). Sorahan et al. (2005) was categorized as follow-up starting before 1970; AML significance level A [relative risk > 1 (p < 0.1)]; exposure assessment quality D (qualitative indication that benzene exposure had occurred). No observed cases were reported for ALL by Sorahan et al. We therefore calculated continuity-corrected relative risks (observed and expected number of cases + 1) and estimated associated 95% confidence intervals with mid-P exact. Values that are different from those in the original analyses are in italic type. aAML significance level categories: A, AML risk estimate > 1 (p < 0.1); B, AML risk estimate > 1 (p < 0.2); C, AML risk estimate > 1 (p > 0.2); D, AML risk estimate reported; E, AML risk estimate not reported. bTwo of three studies reported null cases (continuity correction was applied in the meta-analysis). cOne of two studies reported null cases (continuity correction was applied in the meta-analysis). dNHL or lymphosarcoma/reticulosarcoma (preferred NHL if the study reported both). *p < 0.1 for between-study heterogeneity.